Last updated: October 2026

SKY-0515 is an oral Huntington’s disease treatment candidate being developed by Skyhawk Therapeutics. It uses a small-molecule approach intended to affect RNA processing and reduce production of the disease-causing huntingtin protein.

Current status

SKY-0515 is investigational and is not FDA approved. Its clinical development, trial results, regulatory path, eligibility, timing, and potential cost remain subject to change.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.